This weekend marks the start of the annual meeting of the world’s biggest gathering of cancer doctors, and it’s going to be a big one for Roger Perlmutter, the head of research and development at Merck.

Keytruda, the company’s cancer immunotherapy, is expected to reach annual sales of $10 billion by the end of its fifth year, making it the best drug launch in history over that time period, according to the investment bank Jefferies. But Perlmutter is gushing about the effects the drug has had on survival over that same time frame. New data on that metric will be presented at the upcoming meeting of the American Society of Clinical Oncology.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy